Cancer Anti-Sickness Drug Offers Hope For Hallucinations In Parkinson’s

Parkinson’s UK, the largest charitable funder of Parkinson's research in Europe, is partnering with University College London (UCL), and investing £1 million in a pioneering phase II clinical trial to explore if the drug ondansetron is safe and effective against hallucinations. There are currently 145,000 people living with Parkinson’s in the U.K. and 75% of them will experience visual hallucinations at some point.

The trial comes at a crucial time as a survey carried out by the charity worryingly found that 1 in 10 people with Parkinson’s reported an increase in hallucinations during lockdown . . .